Table 6.

Risk of repeat revascularization for CABG compared to PCI

Group	Crude HR	95% CI	P Value	Adjusted HR	95% CI	P Value
Overall (n=3912)	0.14	0.12, 0.17	<0.001	0.14	0.11, 0.17	<0.001
Preserved kidney Function (n=3405)	0.13	0.11, 0.16	<0.001	0.13	0.11, 0.16	<0.001
Stage 3-5 CKD (n=507)	0.21	0.11, 0.40	<0.001	0.21	0.11, 0.39	<0.001
Stage 3a CKD (n=371)	0.18	0.08, 0.41	<0.001	0.17	0.08, 0.40	<0.001
Stage 3b-5CKD (n=136)	0.30	0.11, 0.85	0.02	0.25	0.09, 0.71	0.01
CKD with multi-vessel disease* (n=400)	0.21	0.10, 0.46	<0.001	0.21	0.10, 0.46	<0.001
CKD with single vessel disease* (n=107)	0.20	0.07, 0.62	0.01	0.19	0.06, 0.61	0.01
CKD proximal LAD disease* (n=329)	0.19	0.09, 0.40	<0.001	0.18	0.09, 0.38	<0.001
CKD without proximal LAD disease* (n=176)	0.25	0.07, 0.87	0.03	0.25	0.07, 0.92	0.04

All models were stratified by trial. Multivariable models adjusted for treatment, age, diabetes, prior myocardial infarction, proximal left anterior descending artery disease, ejection fraction <40%, prior revascularization, and multi-vessel.

^*To avoid model overspecification, these models did not include terms for multi-vessel disease or proximal LAD disease, respectively. CKD-chronic kidney disease. LAD